Introduction: After the introduction of pneumococcal conjugate vaccines, community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae has decreased whereas Staphylococcus aureus and Streptococcus pyogenes could be increasing. These bacteria have been associated with high rates of complications. Aims: (1) To describe the characteristics of pediatric bacterial CAP requiring hospitalization. (2) To compare outcomes according to causative microorganisms. (3) To analyze changes in bacterial CAP rate and etiology over time. Patients and Methods: Retrospective single-center study of inpatients aged 1 month-16 years with culture-confirmed bacterial CAP in 2010-2018 in Madrid, Spain. Results: We included 64 cases (42 S. pneumoniae, 13 S. pyogenes and 9 S. aureus). Culture-confirmed CAP represented 1.48-2.33/1,000 all-cause pediatric hospital admissions, and its rate did not vary over time. However, there was a significant decrease in pneumococcal CAP in the last 3 years of the study (78% of CAP in 2010-2015 vs. 48% in 2016-18, p = 0.017). Median hospital stay was 10.5 days (interquartile range 5-19.5), 38 patients (59%) developed complications and 28 (44%) were admitted to the intensive care unit. Outcomes were similar among children with S. pneumoniae and S. aureus CAP, whereas S. pyogenes was associated with a higher risk for complications (OR 8 [95%CI 1.1-57.2]) and ICU admission (OR 7.1 [95%CI 1.7-29.1]) compared with pneumococcal CAP. Conclusion: In a setting with high PCV coverage, culture-confirmed bacterial CAP did not decrease over time and there was a relative increase of S. pyogenes and S. aureus. Children with CAP caused by S. pyogenes were more likely to develop complications.
Introduction: After the introduction of pneumococcal conjugate vaccines, community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae has decreased whereas Staphylococcus aureus and Streptococcus pyogenes could be increasing. These bacteria have been associated with high rates of complications. Aims: (1) To describe the characteristics of pediatric bacterial CAP requiring hospitalization. (2) To compare outcomes according to causative microorganisms. (3) To analyze changes in bacterial CAP rate and etiology over time. Patients and Methods: Retrospective single-center study of inpatients aged 1 month-16 years with culture-confirmed bacterial CAP in 2010-2018 in Madrid, Spain. Results: We included 64 cases (42 S. pneumoniae, 13 S. pyogenes and 9 S. aureus). Culture-confirmed CAP represented 1.48-2.33/1,000 all-cause pediatric hospital admissions, and its rate did not vary over time. However, there was a significant decrease in pneumococcalCAP in the last 3 years of the study (78% of CAP in 2010-2015 vs. 48% in 2016-18, p = 0.017). Median hospital stay was 10.5 days (interquartile range 5-19.5), 38 patients (59%) developed complications and 28 (44%) were admitted to the intensive care unit. Outcomes were similar among children with S. pneumoniae and S. aureusCAP, whereas S. pyogenes was associated with a higher risk for complications (OR 8 [95%CI 1.1-57.2]) and ICU admission (OR 7.1 [95%CI 1.7-29.1]) compared with pneumococcalCAP. Conclusion: In a setting with high PCV coverage, culture-confirmed bacterial CAP did not decrease over time and there was a relative increase of S. pyogenes and S. aureus. Children with CAP caused by S. pyogenes were more likely to develop complications.
Authors: Chiara Azzari; Daniele Serranti; Francesco Nieddu; Maria Moriondo; Arianna Casini; Lorenzo Lodi; Fernando M de Benedictis; Elisa De Vitis; Federica Cavone; Martina Cortimiglia; Giuseppe Indolfi; Enrico Lombardi; Ines Carloni; Renato Cutrera; Ersilia Lucenteforte; Massimo Resti; Silvia Ricci Journal: Vaccine Date: 2019-04-10 Impact factor: 3.641
Authors: Anne J Blaschke; Caroline Heyrend; Carrie L Byington; Ignacio Obando; Isabel Vazquez-Barba; Elizabeth H Doby; E Kent Korgenski; Xiaoming Sheng; Mark A Poritz; Judy A Daly; Edward O Mason; Andrew T Pavia; Krow Ampofo Journal: Pediatr Infect Dis J Date: 2011-04 Impact factor: 2.129
Authors: Terhi Tapiainen; Saana Launonen; Marjo Renko; Harri Saxen; Eeva Salo; Matti Korppi; Leena Kainulainen; Tarja Heiskanen-Kosma; Laura Lindholm; Jaana Vuopio; Tiina Huotari; Jarmo Rusanen; Matti Uhari Journal: Pediatr Infect Dis J Date: 2016-02 Impact factor: 2.129
Authors: Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin Journal: Lancet Date: 2007-04-07 Impact factor: 79.321
Authors: Christa L Fischer Walker; Igor Rudan; Li Liu; Harish Nair; Evropi Theodoratou; Zulfiqar A Bhutta; Katherine L O'Brien; Harry Campbell; Robert E Black Journal: Lancet Date: 2013-04-12 Impact factor: 79.321